Product: RXR alpha Antibody
Catalog: DF8459
Description: Rabbit polyclonal antibody to RXR alpha
Application: WB
Reactivity: Human
Prediction: Pig, Bovine, Horse, Dog, Chicken
Mol.Wt.: 51kDa; 51kD(Calculated).
Uniprot: P19793
RRID: AB_2841695

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Prediction:
Pig(88%), Bovine(88%), Horse(88%), Dog(88%), Chicken(88%)
Clonality:
Polyclonal
Specificity:
RXR alpha Antibody detects endogenous levels of total RXR alpha.
RRID:
AB_2841695
Cite Format: Affinity Biosciences Cat# DF8459, RRID:AB_2841695.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

FLJ00280; FLJ00318; FLJ16020; FLJ16733; MGC102720; NR2B1; Nuclear receptor subfamily 2 group B member 1; OTTHUMP00000022510; Retinoic acid receptor RXR alpha; Retinoic acid receptor RXR-alpha; Retinoid X nuclear receptor alpha; Retinoid X receptor alpha; RXR alpha1; Rxra; RXRA_HUMAN; RXRalpha1;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P19793 RXRA_HUMAN:

Expressed in lung fibroblasts (at protein level) (PubMed:30216632). Expressed in monocytes (PubMed:26463675). Highly expressed in liver, also found in kidney and brain (PubMed:24275569, PubMed:2159111, PubMed:14702039).

Sequence:
MDTKHFLPLDFSTQVNSSLTSPTGRGSMAAPSLHPSLGPGIGSPGQLHSPISTLSSPINGMGPPFSVISSPMGPHSMSVPTTPTLGFSTGSPQLSSPMNPVSSSEDIKPPLGLNGVLKVPAHPSGNMASFTKHICAICGDRSSGKHYGVYSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYCRYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSANEDMPVERILEAELAVEPKTETYVEANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSELPLDDQVILLRAGWNELLIASFSHRSIAVKDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDMQMDKTELGCLRAIVLFNPDSKGLSNPAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
88
Horse
88
Bovine
88
Dog
88
Chicken
88
Sheep
75
Xenopus
75
Zebrafish
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P19793 As Substrate

Site PTM Type Enzyme
S17 Phosphorylation
T20 Phosphorylation
S21 Phosphorylation
S27 Phosphorylation P17612 (PRKACA)
S32 Phosphorylation
S49 Phosphorylation
S56 Phosphorylation P45983 (MAPK8) , P45984 (MAPK9)
S66 Phosphorylation
S70 Phosphorylation P45984 (MAPK9) , P45983 (MAPK8)
S78 Phosphorylation
T82 Phosphorylation P45984 (MAPK9) , P45983 (MAPK8)
K108 Sumoylation
S129 Phosphorylation
Y147 Phosphorylation
Y150 Phosphorylation
Y249 Phosphorylation P45985 (MAP2K4)
S259 Phosphorylation
S260 Phosphorylation P27361 (MAPK3) , P45984 (MAPK9) , P28482 (MAPK1) , P45983 (MAPK8)
T266 Phosphorylation
K356 Ubiquitination
K364 Ubiquitination
Y397 Phosphorylation
Y403 Phosphorylation
K417 Ubiquitination

Research Backgrounds

Function:

Receptor for retinoic acid that acts as a transcription factor. Forms homo- or heterodimers with retinoic acid receptors (RARs) and binds to target response elements in response to their ligands, all-trans or 9-cis retinoic acid, to regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 to regulate transcription. The high affinity ligand for retinoid X receptors (RXRs) is 9-cis retinoic acid. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone deacetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and coactivators are recruited leading to transcriptional activation. Serves as a common heterodimeric partner for a number of nuclear receptors, such as RARA, RARB and PPARA. The RXRA/RARB heterodimer can act as a transcriptional repressor or transcriptional activator, depending on the RARE DNA element context. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes. Together with RARA, positively regulates microRNA-10a expression, thereby inhibiting the GATA6/VCAM1 signaling response to pulsatile shear stress in vascular endothelial cells. Acts as an enhancer of RARA binding to RARE DNA element. May facilitate the nuclear import of heterodimerization partners such as VDR and NR4A1. Promotes myelin debris phagocytosis and remyelination by macrophages. Plays a role in the attenuation of the innate immune system in response to viral infections, possibly by negatively regulating the transcription of antiviral genes such as type I IFN genes. Involved in the regulation of calcium signaling by repressing ITPR2 gene expression, thereby controlling cellular senescence.

PTMs:

Acetylated by EP300; acetylation enhances DNA binding and transcriptional activity.

Phosphorylated on serine and threonine residues mainly in the N-terminal modulating domain (By similarity). Constitutively phosphorylated on Ser-21 in the presence or absence of ligand (By similarity). Under stress conditions, hyperphosphorylated by activated JNK on Ser-56, Ser-70, Thr-82 and Ser-260 (By similarity). Phosphorylated on Ser-27, in vitro, by PKA. This phosphorylation is required for repression of cAMP-mediated transcriptional activity of RARA.

Sumoylation negatively regulates transcriptional activity. Desumoylated specifically by SENP6.

Subcellular Location:

Nucleus. Cytoplasm. Mitochondrion.
Note: Localization to the nucleus is enhanced by vitamin D3 (PubMed:15509776). Nuclear localization may be enhanced by the interaction with heterodimerization partner VDR (PubMed:12145331). Translocation to the mitochondrion upon interaction with NR4A1 (PubMed:17761950, PubMed:15509776). Increased nuclear localization upon pulsatile shear stress (PubMed:28167758).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in lung fibroblasts (at protein level). Expressed in monocytes. Highly expressed in liver, also found in kidney and brain.

Subunit Structure:

Homodimer. Heterodimer (via C-terminus) with RARA; required for ligand-dependent retinoic acid receptor transcriptional activity; association with RARA is enhanced by pulsatile shear stress. Heterodimer with PPARA (via the leucine-like zipper in the LBD); the interaction is required for PPARA transcriptional activity. Heterodimerizes with PPARG. Heterodimerizes (via NR LBD) with RARB. Heterodimerizes with NR1H4; the heterodimerization enhances the binding affinity for LXXLL motifs from coactivators. Interacts with NCOA3 and NCOA6 coactivators. Interacts with coactivator FAM120B (By similarity). Interacts with coactivator PELP1, SENP6, SFPQ, DNTTIP2 and RNF8. Interacts with PRMT2. Interacts with ASXL1 (By similarity). Interacts with BHLHE40/DEC1, BHLHE41/DEC2, NCOR1 and NCOR2. Interacts in a ligand-dependent fashion with MED1 and NCOA1. Interacts with VDR. Interacts with EP300; the interaction is decreased by 9-cis retinoic acid. Heterodimer (via C-terminus) with NR4A1 (via DNA-binding domain); DNA-binding of the heterodimer is enhanced by 9-cis retinoic acid. NR4A1 competes with EP300 for interaction with RXRA and thereby attenuates EP300 mediated acetylation of RXRA. In the absence of hormonal ligand, interacts with TACC1.

(Microbial infection) Interacts (via the DNA binding domain) with HCV core protein; the interaction enhances the transcriptional activities of the RXRA/RARA and the RXRA/PPARA heterodimers.

Family&Domains:

Composed of three domains: a modulating N-terminal domain (AF1 domain), a DNA-binding domain and a C-terminal ligand-binding domain (AF2 domain).

Belongs to the nuclear hormone receptor family. NR2 subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

References

1). PPARα Agonist Exerts Protective Effects in Podocyte Injury via Inhibition of the ANGPTL3 Pathway. EXPERIMENTAL CELL RESEARCH, 2021 (PubMed: 34499887) [IF=3.7]

Application: WB    Species: Mouse    Sample: podocytes

Fig. 1. Expression of ANGPTL3, LXR α , RXR α , and PPAR α in normal and PAN-treated mouse podocytes. (A) Representative gel image for Lxr, Rxr, Ppar α , Hnf, Pparβ, and Pparγ mRNA expression in unstimulated podocytes (MPC5). A 100 ng sample of RNA from MPC5 was reverse transcribed into single-stranded cDNA. The cDNA was used as a template for PCR. PCR products were resolved in a 1.2% agarose ethidium bromide gel and visualized with ultraviolet light. Real-time RT-PCR analysis (for mRNA expression) (B), western blotting (C), and quantification (D) of ANGPTL3, LXR α , RXR α , and PPAR α in the podocytes after treatment with PAN for 0, 6, 12, 18, and 24 h *P < 0.05, **P < 0.01 vs. 0 h in the same groups.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.